Search research articles
Contact Us
Filters
Showing results (91-100 of 107) with videos related to
Page
of 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 8, 2024
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA
Mazyar Shadman, Talha Munir, Tadeusz Robak, et al.
The Lancet. Haematology
|
July 21, 2019
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial
Anne-Sophie Michallet, Marie-Sarah Dilhuydy, Fabien Subtil, et al.
American Journal of Hematology
|
February 26, 2024
CALR-mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM
Laura Aubin, Rúben Vilas Boas, Rafael Daltro De Oliveira, et al.
Haematologica
|
October 6, 2018
Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes
Sophie Park, Olivier Kosmider, Frédéric Maloisel, et al.
The Lancet. Oncology
|
October 2, 2025
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial
Salomon Manier, Jérôme Lambert, Cyrille Hulin, et al.
Eclinicalmedicine
|
January 8, 2026
Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group
Anne Quinquenel, Rémi Letestu, Magali Le Garff-Tavernier, et al.
Leukemia
|
November 14, 2022
Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO
Pierre-Yves Dumas, Emmanuel Raffoux, Emilie Bérard, et al.
Blood Advances
|
August 4, 2025
Brentuximab Vedotin addition to Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphoma: a LYSA Phase II Study
Olivier Tournilhac, Krimo Bouabdallah, Solene Lecolant, et al.
Leukemia
|
March 13, 2025
Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera
Yan Beauverd, Jean-Christophe Ianotto, Kyaw Htin Thaw, et al.
Blood Advances
|
July 8, 2022
Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs
Marta Sobas, Jean-Jacques Kiladjian, Yan Beauverd, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 107) with videos related to
Sort By:
Page
of 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 8, 2024
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA
Mazyar Shadman, Talha Munir, Tadeusz Robak, et al.
The Lancet. Haematology
|
July 21, 2019
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial
Anne-Sophie Michallet, Marie-Sarah Dilhuydy, Fabien Subtil, et al.
American Journal of Hematology
|
February 26, 2024
CALR-mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM
Laura Aubin, Rúben Vilas Boas, Rafael Daltro De Oliveira, et al.
Haematologica
|
October 6, 2018
Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes
Sophie Park, Olivier Kosmider, Frédéric Maloisel, et al.
The Lancet. Oncology
|
October 2, 2025
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial
Salomon Manier, Jérôme Lambert, Cyrille Hulin, et al.
Eclinicalmedicine
|
January 8, 2026
Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group
Anne Quinquenel, Rémi Letestu, Magali Le Garff-Tavernier, et al.
Leukemia
|
November 14, 2022
Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO
Pierre-Yves Dumas, Emmanuel Raffoux, Emilie Bérard, et al.
Blood Advances
|
August 4, 2025
Brentuximab Vedotin addition to Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphoma: a LYSA Phase II Study
Olivier Tournilhac, Krimo Bouabdallah, Solene Lecolant, et al.
Leukemia
|
March 13, 2025
Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera
Yan Beauverd, Jean-Christophe Ianotto, Kyaw Htin Thaw, et al.
Blood Advances
|
July 8, 2022
Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs
Marta Sobas, Jean-Jacques Kiladjian, Yan Beauverd, et al.
Page
of 11